- Solid Tumors
- Pipeline Molecules
- Alliance Partners
Our mission is to provide healthcare professionals with unbiased clinical research information, easily.
Currently, you can access the following clinical trials being conducted worldwide:
Marizomib is a proteasome inhibitor derived from a novel marine-obligate actinomycete that belongs to the ?-lactone-?-lactam superfamily of proteasome inhibitors.1?In in vitro experiments, marizomib has demonstrated irreversible binding to and inhibition of all 3 proteolytic subunits of the human proteasome complex, resulting in inhibition of proteasome activity.2,3
Celgene acquired this asset from Triphase in 2016. Triphase continues to support marizomib?s development by remaining involved with the ongoing clinical trials.